SUPPLEMENTARY DATA

Title: Efficacy and Safety of Diacerein in Patients with Inadequately Controlled Type 2 Diabetes: a Randomized Controlled Trial.
Authors: Claudia R L Cardoso, MD, PhD; Nathalie C Leite, MD, PhD; Fernanda O Carlos; Andréia A Loureiro; Bianca B Viegas; Gil F Salles, MD, PhD.
Content: Supplemental Tables S1 and S2.

Supplementary Table S1. Cumulative number of participants by treatment group who either increased or decreased concomitant diabetes treatment at each time point of the study.

	12th week	24th week	36th week	48th week
Placebo				
Increase	2	7	9	10
Decrease	2	2	3	4
Diacerein				
Increase	1	1	2	4
Decrease	3	6	7	7

SUPPLEMENTARY DATA

Supplementary Table S2. Adverse events occurring in 5% or more of the participants, according to treatment group.

Adverse event	All participants (n=84)	Placebo (n=41)	Diacerein (n=43)	p-value
Diarrhea, n (%)	35 (42%)	7 (17%)	28 (65%)	<0.001
Nausea/vomiting, n (%)	12 (14%)	2 (5%)	10 (23%)	0.027
Abdominal pain, n (%)	5 (6%)	1 (2%)	4 (9%)	0.36
Headache, n (%)	5 (6%)	3 (7%)	2 (5%)	0.67
Dizziness, n (%)	4 (5%)	2 (5%)	2 (5%)	-----